John Duncan Higgons
CIK 1581954 · Chief Operating Officer · last filed 2022-06-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.35M
Companies
2
Total Filings
46
Lifetime Open-Market Net
-$21.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 9,713 | $1.88 | $18.3K | $67.9K | 12 | 2022-06-28 |
| AGIO | Chief Operating Officer | 120,834 | $35.99 | $4.35M | -$21.43M | 34 | 2016-01-05 |
Recent Filings · Page 2 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-21 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-02 | Jounce Therapeutics, Inc. (JNCE) Delisted | Buy (P) | +6,700 | $107.2K | EDGAR |
| 2016-01-05 | AGIO | Exer (M) | +58,999 | $195.9K | EDGAR |
| 2015-12-17 | AGIO | Sell (S) | −20,000 | -$1.00M | EDGAR |
| 2015-12-07 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2015-11-18 | AGIO | Mixed | — | -$1.21M | EDGAR |
| 2015-10-19 | AGIO | Mixed | — | -$1.41M | EDGAR |
| 2015-10-09 | AGIO | Gift (G) | −70,000 | $0 | EDGAR |
| 2015-10-02 | AGIO | Exer (M) | +10,000 | $3.0K | EDGAR |
| 2015-09-17 | AGIO | Mixed | — | -$1.82M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.